Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01503944 · ClinicalTrials.gov registry record · Phase 1
A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
A Phase 1 study of Parkinson's Disease and Alzheimers Disease, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT01503944 is a Phase 1 study of Parkinson's Disease and Alzheimers Disease that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 30 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01503944, a Phase 1 study of Parkinson's Disease and Alzheimers Disease, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control subjects.
Conditions Studied
Interventions
- DRUG 18F-AV-133
- DRUG 18F-AV-45
Study Locations (2)
Arizona
- Research Site - Sun City
Pennsylvania
- Research Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01503944
The ClinicalTrials.gov registry entry for NCT01503944 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (95% lower). The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which 18F-AV-133 is the first listed.
NCT01503944 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01503944 about?
NCT01503944 is a clinical study titled "A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)". The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control s...
What is the current status of trial NCT01503944?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-03. Estimated completion is 2011-07.
What conditions does trial NCT01503944 study?
This clinical trial studies the following conditions: Parkinson's Disease, Alzheimers Disease, Dementia With Lewy Bodies.
What interventions are being tested in trial NCT01503944?
The interventions under investigation include: 18F-AV-133 (DRUG), 18F-AV-45 (DRUG).
Who is sponsoring clinical trial NCT01503944?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01503944 being conducted?
This trial has 2 study locations across Arizona, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.